Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Hemoglobinopathies
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with hemoglobinopathies. However, the applicability of HSCT has been limited mainly by donor availability, with only 25-30% of patients having human leukocyte antigen (HLA)-matched sibling donors. Previous outcomes using alternate donor options have been markedly inferior due to increased regimen related toxicity, transplant related mortality, graft failure and graft-versus-host disease (GVHD). Advances in transplant technology, including high resolution HLA typing, improved GVHD prophylactic approaches with tolerance induction, and better supportive care over the last decade, are addressing these historical challenges, resulting in increasing donor options.
Source: Seminars in Hematology - Category: Hematology Authors: Feras Alfraih, Mahmoud Aljurf, Adetola Kassim Source Type: research
More News: Hematology | History of Medicine | Stem Cell Therapy | Stem Cells | Toxicology | Transplants